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Abstract
Background: Follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) represent the two most 
frequently utilized laboratory tests in determining ovarian reserve (OR). This study determined the clinical significance 
of their concordance and discordance in female infertility patients.
Methods: We investigated 366 consecutive infertility patients (350 reached IVF), excluding women with polycystic 
ovarian syndrome (PCOS). They were considered to have normal FSH and AMH if values fell within age-specific (as-) 
95% confidence intervals (CI), and to suffer from diminished ovarian reserve (DOR) if FSH exceeded and/or AMH fell 
below those. The two hormones, thus, could be concordant (Group I), both normal (IA) or abnormal (IB), show normal 
AMH/abnormal FSH (Group II) or normal FSH/abnormal AMH (Group III). Oocyte yields, stratified for age categories, 
were then studied in each group as reflection of OR.
Results: Oocyte yields significantly decreased from groups IA to II to III and IB. Predictive values of as-FSH/AMH 
patterns changed, however, at different ages. Except at very young and very old ages, normal as-AMH better predicted 
higher oocytes yields than normal as-FSH, though above age 42 years normal as-FSH predicts good oocyte yields even 
with abnormally low AMH. Under age 42 discrepancies between as- FSH and as-AMH remain similarly predictive of 
oocyte yields at all ages.
Discussion: Concordances and discordances between as-FSH and as-AMH improve OR assessments and predictability 
of oocyte yields in IVF.
Background
A patient's ovarian reserve (OR) determines prognostic
chances of fertility treatments [1,2] and her treatment
options [3-5]. Best possible assessments of OR, therefore,
represent a core issue in modern infertility care. Various
methodologies have been applied to maximize accuracy
of OR determinations, though none has been universally
accepted as superior to others [1,6,7]. Follicle stimulating
hormone (FSH) still represents the most widely utilized
tool in routine daily practice [8,9], though antral follicle
counts and anti-Müllerian hormone (AMH) have
increasingly attracted proponents [8-12].
We in recent years proposed, independent of OR tests
utilized, that normal cut off values be defined in age-spe-
cific (as-) ways [13,14]. Since OR declines with advancing
female age [2], and "normal", therefore, changes, normal
ranges should change in parallel with naturally rising
FSH, declining AMH and decreasing antral follicle
counts. Yet, OR tests only rarely are utilized in as-ways,
diminishing their sensitivity and specificity.
Based on 95% confidence intervals (CI) at various ages,
we in our center's patient population established normal
as-cut off values for FSH [13] and AMH [14] (Figure 1),
demonstrating superiority of as-values over standard cut
offs in defining oocytes yields with in vitro fertilization
(IVF). Since oocytes yields, ultimately, represent the most
accurate reflection of OR, these observations support uti-
lization of as-cut offs over non-age specific values.
FSH and AMH, in principle, correlate and cross-corol-
laries can, indeed, be established [8]. They, however, do
not measure identical OR parameters. FSH mostly
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Page 2 of 7reflects the last two weeks of follicular maturation when
follicles become gonadotropin sensitive, while AMH is
mostly representative of the young, post-primordial to
preantral follicle pool going through earlier stages of folli-
culogenesis [15-17].
These differences are reflected in how both hormones
are utilized in fertility therapy. For example, a number of
studies recently suggested that AMH, better than FSH,
reflects in vitro fertilization (IVF) outcomes, including
pregnancy chances [9,18]. Figure 1, reflecting as-FSH and
AMH levels, also demonstrates this fact by showing at all
ages narrower normal ranges for AMH than FSH and,
therefore, better specificity.
Utilizing a nomogram for as-AMH (Figure 1, upper
panel) and as-FSH (Figure 1, lower panel), despite general
statistical congruity between FSH and AMH [8], many
individual patient will be discordant. What such discor-
dances clinically indicate is, however, unknown and was,
therefore, subject of this investigation.
Methods
Patient selection and stratification
This study investigated 366 consecutively presenting
female infertility patients from whom baseline FSH (cycle
days 2/3) and random AMH were obtained following ini-
tial consultation. Patients with established diagnoses of
polycystic ovary syndrome (PCOS) by history (oligoaa-
menorrhea, hirsutism, obesity), laboratory evaluations
(FSH/LH inversion, androgen excess, insulin resistance)
or ultrasound (polyfollicular ovaries) were excluded but
the study included patients who, either based on labora-
tory or ultrasound evaluation at our center, were for the
first time diagnosed with PCOS.
Our center's patient population at all ages includes a
disproportionally high number of women with dimin-
ished ovarian reserve (DOR) [13]. It, therefore, does not
necessarily reflect typical populations seen in most fertil-
ity centers. In documentation, Table 1 summarizes
patient characteristics.
Amongst 366 consecutive patients, 350 had reached a
first IVF cycle for which cycle outcomes, including
oocytes yields, were available by time of this data assess-
ment. Patients were stratified into the following age cate-
gories: < 34.0; 34.0-35.9; 36.0-37.9; 38.0-39.9; 40.0-41.9;
and ≥ 42 years. Within each age category, they were con-
sidered to have age-appropriate or abnormal as-FSH and
AMH levels. Normal as-levels for FSH and AMH for our
patient population have previously been reported [13,14]
and are demonstrated graphically in Figure 1.
Patients were then assessed in four groups: Group [IA],
as-FSH and -AMH were both in normal range; [II], as-
AMH normal and as-FSH abnormal (high); [III], as-AMH
abnormal (low) and as-FSH normal and, finally, [IB], both
at abnormal as-ranges (FSH high and AMH low). Oocyte
yields and other IVF cycle outcome parameters were
recorded in first IVF cycles.
DHEA supplementation and ovarian stimulation
Since our center routinely supplements DOR patients
with dehydroepiandrosterone (DHEA) prior to IVF
cycles [19], the high prevalence of DOR in our patient
population (Table 1) resulted in supplementation to
patients at all ages in Groups IB, II and III and also to
women above age 38 years in Group IA. Following at least
six weeks of DHEA supplementation, patients are then
stimulated in their first cycle with a microdose agonist
cycle with FSH preponderance (at least 300 IU) and
human menopausal gonadotropin (hMG, 150 IU) [20].
This means that all patients in Groups IB, II and III and
women above age 38 years in Group IA received such
high dose gonadotropins stimulation. Group IA patients
under age 38 years uniformly received ovarian stimula-
tion in a long agonist protocol with maximally 300 IU of
Figure 1 Individual FSH and AMH levels against nomogram of as- 
levels*. * Some scatters fell outside the shown nomogram field and, 
therefore, are not shown. as- FSH and AMH levels, represented by the 
nomogram were established based on 95% CI of FSH and AMH levels 
of an infertile patient population [30].
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and FSH. IVF is performed in routine fashion and
embryos are transferred on day-3 after retrieval.
Estradiol, FSH and AMH were assayed in house, as pre-
viously reported {Estradiol and FSH [21]; AMH [22]}, uti-
lizing standard ELISA assays (AIA-600 II, Tohso, Tokyo,
Japan and Diagnostic Systems Laboratories, Inc. Webster,
TX 77598-4217, USA, respectively).
Statistics
Normally distributed data were compared by means of
one-way analysis of variance test. All data are expressed
as mean ± standard deviation; a p-value < 0.05 was con-
sidered statistically significant. All analyses were carried
out with SPSS software for Windows version 17.0, 2005
(SPSS Inc. Chicago, IL)
Institutional Review Board
Patients, at time of initial consultation, sign an informed
consent form, allowing review of medical records for
research purposes as long as patient identity remains pro-
tected and records remain anonymous. Studies involving
record review, and meeting these criteria, therefore,
undergo expedited review by the center's Institutional
Review Board (IRB). Confirmation from the center's IRB
chairman is available upon request. The center also, in
addition, maintains a protected electronic research data
collection system with controlled access, which guaran-
tees that above noted conditions are met.
Results and Discussion
Mean age for these 350 women was 37 ± 5.6 years; mean
FSH was 17.0 ± 0.93 mIU/mL, while mean AMH was 1.59
± 0.12 ng/mL. Table 2 offers mean FSH and AMH levels
for the six age categories.
Figure 1 demonstrates individual FSH and AMH values
against a previously established nomogram of as-levels.
Since PCOS patients were excluded, and since the pur-
pose of this study was definition of DOR, only lower cut
off values of AMH are relevant.
Amongst 350 IVF patients 229 (65.8%) were concor-
dant in FSH and AMH in that they were either age-spe-
cifically normal or abnormal in both (Group I). Fifty
(14.4%) showed normal as- values (Group IA) and 166
(47.7%) abnormal values in both hormone (Group 1B);
115 (33.1%) were discordant in that as-AMH was normal
and as-FSH was abnormally high (Group II); and 19
patients (5.5%) were discordant with abnormally low as-
AMH and normal as-FSH (Group III). Table 1 summa-
rizes their characteristics.
As Table 1 demonstrates, ages did not differ between
groups. FSH levels, however, progressively increased (F =
17.7, df = 3, p < 0.001 and AMH (F = 40, df = 3, p < 0.001)
as well as oocyte yields (F = 22.2, df = 3, p < 0.001) pro-
gressively decreased from Group IA to Group II and
Group III and, finally, Group IB.
Figure 2 translates these findings into an assessment of
OR based on oocyte yields. As the figure demonstrates,
oocyte yields were at all ages uniformly the highest in
Group IA. At youngest ages (≤ 34 years) Groups IA and II
produce practically identical oocyte yields, as do Groups
III and IB, though the latter two at significantly reduced
numbers (Groups IA, II: 15.0 ± 9.9, n = 48; Groups III, IB,
9.3 ± 5.9 N = 45, P = 0.001). At age categories 34-36
through 42, oocyte yields appear to follow the general OR
trend, outlined in Table 2, from Group IA to Group II, to
Group III and Group IB. At older age (>42), oocyte yields,
however, become more erratic, with Groups IA and III
Table 1: Patient characteristics of patients reaching IVF, based on 
concordance or discordance between as-FSH and as-AMH
IA II III IB
N 48 115 19 168
Age (years)* 36.7 ± 4.8 37.5 ± 5.3 36.2 ± 
6.6
38.3 ± 5.2
FSH (mIU/mL)** 6.5 ± 1.1 15.1 ± 12.8 6.6 ±. 9.0 23.0 ± 21.3
AMH (ng/mL)** 3.42 ± 0.8 2.7 ± 3.0 0.6 ± 0.5 0.5 ± 0.4
Oocytes (n)** 13.1 ± 7.6 10.9 ± 7.3 9.1 ± 8.2 5.9 ± 5.2
Race: n (%)
African America 10(18.5%) 16(29.6%) 2(3.7%) 26(48.1%)
Asian 11(19.6%) 21(37.5%) 3(5.4%) 21(37.5%)
Caucasian 25(11.5%) 72(33.0%) 11(5.0%) 110(50.5%)
Middle Eastern 2(9.1%) 6(27.3%) 3(13.6%) 11(50.0%)
Primary Infertility Diagnoses: n (%)***
DOR 14(9.0%) 44(28.2%) 6(3.8%) 92(59.0%)
Endometriosis 2(10.5%) 5(26.3%) 1(5.3%) 11(57.9%)
Male 12(12.1%) 37(37.4%) 7(7.1%) 43(43.4%)
Other 2(10.5%) 9(47.4%) 2(10.5%) 6(31.6%)
PCO 8(36.4%) 9(40.9%) (0.0%) 5(22.7%)
Tubal 10(30.3%) 10(30.3%) 3(9.1%) 10(30.3%)
Uterine 0(0.0%) 1(50.0%) 0(0.0%) 1(50.0%)
* Age does not significantly differ between groups;
**FSH, however, progressively increases (p < 0.001) and AMH and 
oocytes progressively decreased across categories from groups IA, to 
II, III and IB (p < 0.001).
*** Percentages add up to 100% within each primary diagnosis. By far 
the most frequently represented primary diagnosis (156/350 
patients, 44.6%) was DOR. Amongst those patients Group IB was 
significantly more prevalent than the three other study groups (p < 
0.01).
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yields than Groups II and IB. (Group 1A, III: 11.6 ± 9.5, 
n = 10; Group III, 1B: 5.4 ± 4.4, p = 0.001).
Correct definition of OR is a corner stone of infertility
therapy. It, therefore, is not surprising that investigators
are attempting to improve OR assessments. Amongst
methods currently utilized, FSH and AMH appear to
have achieved primacy [6,7,9,12-16,18]. Both define OR
reasonably well and, in principle, correlate [8]. They,
however, do, as this study suggests, diverge in 38.3 per-
cent of cases (Table 1)
We [9,14] and others [18] demonstrated that AMH
offers better clinical specificity than FSH in regards to
IVF outcome parameters, including establishment of
pregnancy. This is also suggested by the fact that normal
as-AMH levels, as shown in Figure 1, at all ages are in a
narrower range than is as-FSH.
Better specificity for AMH should not surprise because
AMH reflects the post-primordial and pre-antral follicle
population, while FSH is mostly reflective of late-stage
follicles in the gonadotropin-sensitive stage, preceding
ovulation by only approximately two weeks [15-17].
AMH, therefore, better reflects the follicle "pool," though
an ideal measurement of OR should, likely, also include
the still unrecruited primordial follicle pool.
These follicle populations change with advancing
female age. Follicle recruitment declines and follicles
reaching gonadotropin sensitivity also decline in num-
bers [23] One, therefore, can expect that FSH and AMH
may differently reflect OR at different ages.
This hypothesis was, indeed, confirmed in this study,
which investigated the meaning of concordance and dis-
cordance between as- FSH and as-AMH levels at varying
ages. We chose to investigate as-hormone, rather than
non-age specific, levels because we have previously dem-
onstrated that as-OR testing with FSH and AMH is supe-
rior in predicting oocyte yields to non-age-specific
testing [13,14].
Table 2: Age-stratified as-AMH and as-FSH levels in all four study 
groups
Age (years) Group N AMH (ng/mL FSH (mIU/mL)
≤ 34.00 IA 1
7
5.1 ± 2.6 6.1 ± 0.5
II 3
1
4.0 ± 2.0 14.5 ± 17.3
III 1
0
0.9 ± 0.5 6.3 ± 0.9
IB 3
5
0.9 ± 0.5 20.4 ± 15.9
34.01 - 36.00 IA 4 2.2 ± 0.6 6.0 ± 0.8
II 1
6
4.3 ± 6.7 11.6 ± 7.5
III - - -
IB 1
1
0.4 ± 0.4 16.8 ± 10.9
36.01 - 38.00 IA 5 2.6 ± 0.7 6.3 ± 1.5
II 8 3.3 ± 2.4 11.2 ± 3.5
III 1 0.6 6.0
IB 2
5
0.7 ± 0.4 18.0 ± 15.0
38.01 - 40.00 IA 7 4.4 ± 4.9 6.9 ± 1.3
II 1
5
1.9 ± 1.0 13.9 ± 7.1
III 2 0.3 ± 0.1 7.8 ± 0.4
IB 2
9
0.5 ± 0.3 22.7 ± 20.8
40.01 - 42.00 IA 1
0
1.8 ± 1.4 6.9 ± 1.5
II 1
7
1.4 ± 1.0 16.7 ± 12.0
III 1 0.3 6.3
IB 2
4
0.3 ± 0.2 23.9 ± 17.1
> 42.00 IA 5 1.7 ± 1.2 7.0 ± 1.0
II 2
8
1.3 ± 0.7 17.8 ± 13.2
III 5 0.2 ± 0.2 6.8 ± 0.8
IB 4
4




1.6 ± 2.4 16.1 ± 14.3
Figure 2 as-Oocyte yield, based on concordance or discordance 
of as-FSH and as-AMH*. * Groups are color-coded in accordance with 
legend in figure.
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jects, FSH increases and AMH as well as oocyte yields
decline from Group IA (both hormones in normal as-
range) to Group II (AMH normal, FSH elevated), to
Group III (FSH normal, AMH low) to Group 1B (FSH
abnormally high, AMH abnormally low).
This observation suggests that, in principle, normal
AMH is more important than normal FSH. Figure 2,
however, demonstrates a more complicated picture when
data are analyzed based on age categories. The figure
shows that in the youngest patient group (≤ 34 years),
based on oocyte yields, there is really no difference in OR
between women in Groups IA and II, just as there is no
difference in oocyte yields between Groups III and IB,
with the latter two groups, both, significantly lower than
the first two. Young infertility patients with DOR, there-
fore, will still have excellent oocyte yields whether AMH
and FSH or whether only AMH is in normal range. They
will, however, have clearly reduced oocyte yields if only
FSH is in normal range or both hormones are abnormal.
This finding correlates with the previously reported
observation that elevated FSH in younger females is
much less ominous than in older patients [24,25] but sug-
gests that this observation only applies if AMH is still in
normal range. These observations, thus, once more, dem-
onstrate superiority of AMH over FSH in reflecting OR in
younger patients.
At age 34, this pattern, however, starts changing:
Between ages 34 and 42 years, oocyte yields follow the
declining oocyte yield pattern of the whole study group,
noted in Table 1, with largest egg numbers in Group IA,
declining in Group II, further declining in Group III and,
ultimately, being the lowest in Group IB. In this age cate-
gory being normal in both hormone parameters (Group
IA), uniformly, reflects best prognosis for good oocyte
yields, followed in order by normal AMH/abnormal FSH
(Group II), normal FSH/abnormal AMH (Group III) and
both values abnormal (Group IB). At that age range, nor-
mal AMH is, therefore, also clearly better than normal
FSH in predicting better oocyte yields. Indeed, once
AMH levels are abnormal, even if FSH is still normal
(Group III), oocyte yields are low in comparison.
Figure 2 also demonstrates that, above age 42, this pic-
ture once again, changes. At such advanced age, normal
FSH better predicts nominally higher oocyte yields than
AMH as Group III (normal FSH, abnormal AMH), pro-
duces surprisingly good oocyte yields, - indeed, similar to
those of Group IA (though these trends do not achieve
statistical significance). Why normal FSH at such
advanced female age would have such a positive predic-
tive value in comparison to AMH remains to be deter-
mined and is currently still under investigation. It is
tempting to speculate that normal FSH at this age is (via
negative feedback) reflective of normal follicular estradiol
production, and, therefore, suggestive of better quality
follicles. Alternatively, abnormally low AMH could be
unable to inhibit follicular recruitment and, the in Group
III observe constellation in women above age 42 years
could, simply, reflect a subgroup of women who at this
advanced age still more actively recruit follicles.
As we already previously reported [26,27], these data,
once again, confirm that accurate OR assessments are the
most difficult at youngest and oldest ages. This fact is also
demonstrated in the widening ranges of normal FSH and
AMH values (Figure 1) at both age extremes. Why that
should be is, once again, speculative but it seems likely
that these wider ranges of normal, simply, are reflective of
greater heterogeneity of ovarian function at very young
and old ages.
Figure 1, however, also demonstrates that normal as-
ranges for FSH and AMH are the narrowest at approxi-
mately ages 33 to 34 years. As noted before, this is exactly
the age break point in this study between younger women
with the typical FSH/AMH pattern of younger age and
the vast majority of middle aged patients with the previ-
ously described declining oocyte yield pattern from
Groups IA to II, III and IB. Interestingly, this is also the
age, where the OR of women with normal CGG counts
on the FMR1 (fragile X) gene falls below the OR of
heterozygous-abnormal women [28].
Combined, these last two observations suggest that
heterogeneity of OR at very young and old ages may be
genetically predetermined. As OR declines with advanc-
ing age, heterogeneity is lost and the age of approximately
34 years appears to represents an important switching
point in human OR.
Figure 2 also allows for additional observations: When
Group I patients are followed longitudinally from young-
est to oldest ages, mean oocyte yields decrease remark-
ably little. Indeed, even women above age 42 still produce
an average of over 10 oocytes per cycle. This may sur-
prise, considering that most here investigated patients
were afflicted by DOR (Table 1), usually characterized by
ovarian resistance to stimulation with gonadotropins and
poor oocyte yields [29]. Indeed, some investigators
equate these two conditions and the literature, therefore,
often defines DOR as retrieval of four or less oocytes [30].
Such definitions, however, for a number of reasons, do
not apply here: First, the here utilized definition of DOR
relies on as- FSH and AMH levels, which previously have
been demonstrated to differentiate between significantly
lower and higher oocyte yields [13,14]. Second, most here
investigated patients, because of DOR diagnoses, were
supplemented with dehydroepinadrosterone (DHEA),
which has been reported to improve oocyte yields signifi-
cantly [19]. Finally, because of DOR, most patients in this
study received maximal ovarian stimulation with at least
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cycle [20].
In short, as-OR evaluations offered more sensitive
DOR detection prior to stimulation, while DHEA and
appropriately chosen ovarian stimulation protocols
enhanced oocyte yields. Better than expected oocyte
yields in this patient population should, therefore, not
surprise, though even we were surprised by how excellent
yields were in some women of very advanced ages (Figure
2).
As expected, all four patient groups demonstrated
decreasing oocyte yields with advancing age. They uni-
formly, however, were small: Groups IA and II, with best
oocyte yields at very young ages, maintain their numeri-
cal advantage up to age 42 years. Similarly, Groups III and
IB, at young ages demonstrating significantly reduced
oocyte yields, remain at retrieval numbers significantly
below those of the other two groups until age 42. Only
above age 42, Group III suddenly breaks out with surpris-
ingly excellent oocyte numbers.
These slow and persistent decreases in oocyte yields
with age in each of the four groups suggest a genetically
preprogrammed OR pattern, observable from early age
on. The data, therefore, resemble OR patterns we
described in infertility patients, based on normal,
heterozygous or homozygous abnormal FMR1 status
[28]. We, therefore, are currently investigating whether
the patients' here observed FSH/AMH patterns correlate
to their FMR1 status.
Conclusions
This study defines four specific FSH/AMH patterns and
their effects on oocyte yields at different ages. While
women with normal as-FSH and normal as-AMH at all
ages produce the best oocyte yields, women with normal
as-AMH but abnormal as-FSH do not follow far behind
until age 42. In contrast to these two groups, women with
normal as-FSH but abnormal as-AMH and those with
abnormal as-FSH and -AMH at all ages, up to 42 years,
demonstrate significantly reduced oocyte yields. After
age 42, there is little difference between women with nor-
mal FSH and AMH and with either one at abnormal lev-
els. Only women with both hormones at abnormal levels
produce reduced egg numbers.
The prospective assessment of as-FSH and -AMH, in
combination with female age, thus, can help in predicting
oocyte yields in women with infertility. Here presented
data should, however, be viewed with caution since stud-
ied patients were almost uniformly affected by DOR and,
therefore, under DHEA supplementation. Whether these
data are also applicable to unsupplemented infertility
patients remains to be established.
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